[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-symptoms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,45,68,104,129,159,189,215,243,270,299,327,350,370,392,420,442,476,512,534,561],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642375","gutcheck-optimization-of-a-personalized-mobile-health-app-for-survivors-of-gastrointestinal-cancer-100642375",false,"NCT07661017","GutCheck: Optimization of a Personalized Mobile Health App for Survivors of Gastrointestinal Cancer","Inclusion\n\nSurvivors of GI cancer are eligible if they are:\n\n* ≥18 years old\n* reside in or have received cancer care in Minnesota\n* own a smartphone • consent to install the GutCheck app and discontinue diet tracking in other lifestyle apps (e.g., MyFitness, Fitbit, Noom).\n* are English-speaking\n* have received a GI cancer diagnosis (e.g., esophageal, gastric, colorectal, liver, pancreatic, etc)\n* At least 2 months post-cancer treatment\n\nInclusion criteria for oncology specialists (oncologists, advanced practice providers, nurses, dietitians, and patient navigators) include:\n\n* Have interacted with at least 1 cancer patient or survivor in the past month.\n* Have experience working with electronic health records (EHR).\n\nExclusion\n\n* Currently pregnant (Patient Study ONLY)\n* Pregnancy status may be self-reported by the participant.\n* Individuals who are postmenopausal, surgically sterile, or otherwise unable to become pregnant are not subject to this exclusion.\n* Active cancer or receiving treatment for another cancer.\n* Currently taking or has taken antibiotics in the last 3 months.\n* Diagnosis of inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), and\u002For celiac disease.\n* Involuntary weight loss of 10% or more of usual body weight within 6 months, or involuntary loss of 5% or more of usual body weight in 1 month.\n\nOncology specialists' exclusion criteria include:\n\n* Unable to participate in an interview",true,"ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","There are two components to the study: a patient and a clinician study. The clinician study will include one-hour semi-structured interviews with oncology specialists to identify facilitators and barriers to integrating digital diet interventions into the clinical workflow, and to understand their needs and preferences for digital diet interventions. The patient study aims to investigate initial feasibility, efficacy and acceptability of the GutCheck app and intervention. It will last 9 weeks and involves 2 study visits and 2 active phases with a transition week and optional transition visit between phases. During active phases, participants will be asked to use the GutCheck app every day. Prior to the first active phase, participants will go through informed consent and app training. The first active phase will last two weeks and will focus on tracking participants' diet, gastrointestinal (GI) symptoms, and stress. The data collected during the first active phase will be used to identify any potential trigger foods that may contribute to GI symptoms, but only if the participant reports experiencing GI symptoms. Between active phases, participants will have one Transition Week, where results from the first phase are given to the participants with the option to attend a Transition Week Visit. The second active phase will last four weeks and will involve the message intervention. A single-blind, micro-randomized trial design will be used to repeatedly randomize participants to different intervention combinations, determining both the timing and frequency of intervention message delivery throughout the day. Lastly, there will be an exit visit and interview within a week from the intervention to collect post-intervention measures and ask about the participant's experience with the GutCheck app.",[26,27,28,29,30,31,32],"Gastrointestinal","Mobile Health","Gastrointestinal Symptoms","Gut Health","Gastrointestinal Cancer","Survivorship","GI Cancer","NOT_YET_RECRUITING","2026-06-16",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":20},"2026-12",{"date":41,"type":20},"2030-06",{"name":43,"class":44},"Masonic Cancer Center, University of Minnesota","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100642936","gastrointestinal-health-survey-of-dalian-college-students-100642936","NCT07634887","Gastrointestinal Health Survey of Dalian College Students","Questionnaire Survey and Analysis on the Current Status and Influencing Factors of Gastrointestinal Health Among College Students in Dalian","Inclusion Criteria:\n\n1. Aged between 18 and 25 years, and currently enrolled as a full-time undergraduate student at a university in Dalian, China.\n2. Voluntarily participates in the study and provides online informed consent.\n3. Able to independently complete and submit the entire questionnaire.\n\nExclusion Criteria:\n\n1. Individuals with severe organic gastrointestinal diseases or those who have undergone gastrointestinal surgery recently.\n2. Individuals on long-term medication that affects gastrointestinal function.\n3. Questionnaires that are incomplete, contain logical contradictions, or are submitted more than once by the same participant.","25 Years",{"count":54,"type":20},1020,"OBSERVATIONAL","This is a cross-sectional study aimed to investigate the current status of gastrointestinal health among full-time undergraduate students aged 18-25 years in Dalian, and to clarify the influences of factors such as diet, sleep, psychological mood, and antibiotic use on gastrointestinal symptoms, as well as gender differences. The study plans to enroll 1020 eligible college students and collect information including demographics, gastrointestinal symptoms in the past month, lifestyle, and medication use. Statistical analyses will be performed using the chi-square test, Mann-Whitney U test, Spearman correlation analysis, and multivariate logistic regression. The primary objective is to assess the prevalence and distribution characteristics of gastrointestinal discomfort among college students; the secondary objectives are to identify independent risk factors and analyze gender differences. The results of this study will provide data support for colleges and universities to carry out gastrointestinal health education, schedule and dietary interventions, and rational medication guidance, as well as evidence-based basis for improving digestive health in young populations.",[28],"2026-06-08",{"date":60,"type":37},"2026-06-09",{"date":62,"type":20},"2026-05-15",{"date":64,"type":20},"2027-05-14",{"name":66,"class":67},"DiproBio (Shanghai) Co., Ltd.","INDUSTRY",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100643167","evaluation-of-metabolic-parameters-intestinal-permeability-and-gastrointestinal-symptoms-after-bariatric-surgery-in-body-weight-management-100643167","NCT07643376","Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management","Evaluation of Postoperative Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms in Body Weight Management After Laparoscopic Sleeve Gastrectomy","METABAR","Inclusion Criteria:\n\n* Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month\n* Aged between 19-50 years\n* BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities\n* Signed informed consent form\n* Non-smoker and non-alcohol dependent\n\nExclusion Criteria:\n\n* Did not undergo or is not planned to undergo LSG\n* Outside the age range of 19-50 years\n* Did not sign the informed consent form\n* BMI \\\u003C40 kg\u002Fm² or BMI \\\u003C35 kg\u002Fm² without obesity-related comorbidities\n* Smoker or alcohol dependent\n* Has an inflammatory disease\n* Currently using probiotics, antibiotics, or fiber supplements\n* Has a psychiatric disorder","19 Years","50 Years",{"count":79,"type":20},40,"This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.\n\nObesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.\n\nIn this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:\n\n* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels\n* Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels\n* Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)\n* Anthropometric measurements: body weight, height, waist and hip circumference, BMI\n* Nutritional intake: 3-day dietary records\n\nThe study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.",[82,83,84,28,85],"Obesity, Morbid","Bariatric Surgery","Intestinal Permeability","Metabolic Syndrome",[87,88,89,90,91,92,93,94],"Laparoscopic Sleeve Gastrectomy","Zonulin","Secretory IgA","Lipopolysaccharide","GSRS","Body Weight Management","Gut microbiota","Postoperative Metabolic Parameters",{"date":96,"type":37},"2026-06-11",{"date":98,"type":20},"2026-07-01",{"date":100,"type":20},"2027-02-01",{"name":102,"class":44},"Toros University",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":15,"sex":112,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":103},"100637734","the-effects-of-postbiotic-supplementation-in-female-athletes-100637734","NCT07580118","The Effects of Postbiotic Supplementation in Female Athletes","The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes. A Double-blinded Randomised Controlled Trial.","GIJane","Inclusion Criteria:\n\n1. Female, cisgender, premenopausal.\n2. Minimum age 18 years.\n3. Regular, natural menstrual cycle (21-35 days in duration), with 9 or more consecutive periods per year, if possible documented with tracker apps, calendars, or other tools\n4. Ability to give informed consent.\n5. Body mass index (BMI) ≥ 18.5 and \\\u003C 24.9 kg\u002Fm²\n6. Agreeing to maintain lifestyle habits during the study (same dietary and physical activity habits)\n7. Having a smartphone and a history of consistent tracking of training and health records via apps.\n8. Having regular GI issues during exercise, and during menstruation. During pre-screening, this will be assessed with a shortened GSRS questionnaire, where participants need to have had, in the month preceding pre-screening, the equivalent of at least a score of 2 in a GSRS focus area (diarrhoea, pain, indigestion).\n9. No relevant self-reported abnormalities from medical history.\n10. Trained athlete (trains at least 3 times per week for more than 1 hour per day and who has been involved in endurance training for at least 2 years in alignment with previous research (Pfeiffer et al., 2010). This will be evaluated by assessing training records (Strava or similar applications, certificates of attendance at athletic events, club membership, etc.).\n11. Access to a health-care provider, who can be contacted by the CRO, and who reside in areas with available emergency health services.\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, lactating, or plan to become pregnant before study end.\n2. Individuals with secondary amenorrhea.\n3. Individuals who use hormonal contraceptives during the last 6 months before (and during) the trial.\n4. Individuals who are currently participating in another clinical trial or have participated in a trial within the last two months prior to enrolment.\n5. Tobacco smokers and vapers.\n6. Individuals with acute illnesses.\n7. Individuals with a current musculoskeletal injury or one within the last month.\n8. Individuals taking probiotic supplements or have taken probiotics two weeks prior to enrolment.\n9. Individuals controlling chronic diseases with treatments known to alter the intestinal microbiome or to alter GI symptoms, such as certain pain killers, antacids, proton pump inhibitors, anti-diarrhoeal medication or supplements, and laxatives.\n10. Individuals having received antibiotics treatments within three months of trial start.\n11. Individuals having planned major changes in lifestyle (i.e. diet, weight loss program, exercise level, travelling) during the duration of the study.\n12. Individuals who have hypersensitivity\u002Fallergy to any of the components of the test product.\n13. Individuals who have planned major elective surgery during the study period.","FEMALE",{"count":114,"type":20},100,[23],"The goal of this clinical trial is to learn if a postbiotic supplement can reduce stomach and gut symptoms in physically active women.\n\nThe main questions it aims to answer are:\n\nDoes the supplement reduce gut symptoms during the menstrual cycle? Does it improve symptoms related to exercise?\n\nResearchers will compare the postbiotic supplement to a placebo (a look-alike capsule that contains no active ingredient) to see if the supplement works.\n\nParticipants will be physically active, premenopausal female athletes.\n\nParticipants will:\n\nTake either the postbiotic supplement or a placebo each day for two menstrual cycles Track their menstrual cycle and training Report gut symptoms using regular questionnaires Provide stool samples to assess gut health\n\nThis study will help researchers understand whether postbiotic supplements can improve gut health and reduce symptoms that may affect training and performance in female athletes.",[28,118],"Menstrual Cycle","RECRUITING","2026-05-29",{"date":122,"type":37},"2026-06-02",{"date":124,"type":37},"2026-05-05",{"date":126,"type":20},"2027-05-30",{"name":128,"class":44},"Liverpool John Moores University",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":103},"100638045","impact-of-dietary-fibre-supplementation-on-gut-symptoms-in-healthy-participants-100638045","NCT07587424","Impact of Dietary Fibre Supplementation on Gut Symptoms in Healthy Participants","The Effect of Dietary Fibre Supplementation on Gastrointestinal Symptoms in Healthy Participants - KiVa-trial","KiVa","Inclusion Criteria:\n\n* healthy male and female\n* aged 18-65 years\n* experience gastrointestinal discomfort during or after eating\n* willing to commit to the 6-week study period and follow the study schedule.\n\nExclusion Criteria:\n\n* Body mass index ≤ 18.5 or ≥ 35 kg\u002Fm².\n* Inflammatory bowel diseases, irritable bowel syndrome (IBS), celiac disease, endocrine or lipid metabolism disorders, liver or kidney diseases, cancer within the past 5 years, eating disorders.\n* Medication for gastrointestinal symptoms, bowel function, diabetes, or hypercholesterolemia.\n* Regular or recent use of antibiotics (within the last 3 months).\n* Food allergies to the ingredients of the study products.\n* Heavy, long-duration exercise several times a week.\n* Smoking, use of snus or nicotine pouches.\n* Planned or ongoing pregnancy or breastfeeding.\n* In addition, the site-specific principal investigator may exclude a person due to any illness, medication, or factor they deem relevant for the participant's health and safety or for the conduct of the study.","65 Years",{"count":139,"type":20},28,[23],"Fibres found in food are mainly carbohydrates that are not broken down or absorbed during human digestion but instead pass to the colon to be fermented by microbes. Gases produced during bacterial fermentation (hydrogen, methane, and carbon dioxide), can cause unpleasant gastrointestinal symptoms in some individuals, such as bloating, flatulence, and stomach pain. Gas production varies between individuals and is influenced by the chemical structure of dietary fibres, the gut microbes' ability to ferment fibre, intestinal pH, and the transit time of intestinal contents. This randomized clinical trial in healthy adults will investigate how individual variations in the microbiome influence the level of gastrointestinal (GI) symptoms induced by different fibre types during short-term exposure.",[28],[144,145,146,147,148,149],"dietary fibre","dietary fiber","gut symptoms","microbiota","microbiome","gastrointestinal discomfort","2026-05-07",{"date":152,"type":37},"2026-05-14",{"date":154,"type":20},"2026-08-17",{"date":156,"type":20},"2026-09-30",{"name":158,"class":44},"University of Helsinki",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":112,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":174,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":103},"100635339","effects-of-music-therapy-breathing-exercises-and-virtual-reality-on-obstetric-recovery-pain-and-gastrointestinal-symptoms-after-cesarean-section-100635339","NCT07551401","Effects of Music Therapy, Breathing Exercises, and Virtual Reality on Obstetric Recovery, Pain, and Gastrointestinal Symptoms After Cesarean Section","Comparative Investigation of the Effects of Music Therapy, Breathing Exercises, and Virtual Reality Application on Obstetric Recovery, Pain, and Gastrointestinal Symptoms Following Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 years and older\n* Able to speak and understand Turkish\n* Gestational age between 37 and 42 weeks\n* Undergoing cesarean section under spinal anesthesia\n* Able to communicate and willing to participate\n* No major intraoperative or early postoperative complications (within 0-12 hours), such as severe hemorrhage (\\>1000 mL), anesthesia-related cardiorespiratory complications, major surgical complications, wound dehiscence, sepsis, or need for intensive care\n* No visual or hearing impairments\n* Having a live, healthy, singleton newborn\n\nExclusion Criteria:\n\n* Passage of flatus before the intervention\n* Presence of any diagnosed medical condition during pregnancy\n* Development of maternal postpartum complications such as postpartum hemorrhage (\\>1000 mL), infection, wound dehiscence, sepsis, thromboembolism, or need for intensive care\n* Presence of neonatal complications such as neonatal distress requiring intensive care, congenital anomalies, severe respiratory distress, infection, or perinatal mortality\n* History of chronic pain, gastrointestinal disease, or respiratory disease\n* Diagnosed and treated psychiatric disorders",{"count":167,"type":20},192,[23],"Cesarean section is a common surgical procedure performed to deliver a baby when vaginal birth may pose risks to the mother or infant. Although it is often life-saving, recovery after cesarean section is frequently associated with multiple physical and psychological challenges, including postoperative pain, delayed gastrointestinal function, reduced mobility, fatigue, and decreased overall well-being. These factors may negatively affect a woman's ability to care for her newborn, initiate breastfeeding, and adapt to the postpartum period.\n\nIn recent years, there has been increasing interest in non-pharmacological interventions that can safely support postoperative recovery without causing additional side effects. Among these, music therapy, breathing exercises, and virtual reality applications have been identified as promising approaches. Music therapy may promote relaxation and reduce pain and anxiety through auditory stimulation and emotional regulation. Breathing exercises may enhance parasympathetic activity, improve oxygenation, reduce stress, and support gastrointestinal motility. Virtual reality applications, by providing immersive audiovisual experiences, may reduce pain perception, decrease anxiety, and improve overall comfort through distraction and relaxation mechanisms.\n\nAlthough these interventions have individually demonstrated beneficial effects in postoperative care, the existing literature is limited in directly comparing their relative effectiveness within the same study design. Furthermore, most studies have primarily focused on pain outcomes, while other important aspects of recovery, such as obstetric recovery quality and gastrointestinal symptoms, have received less attention.\n\nThis randomized controlled trial aims to comparatively investigate the effects of music therapy, breathing exercises, and virtual reality application on obstetric recovery, pain, and gastrointestinal symptoms in women following cesarean section. Participants will be randomly assigned to one of three intervention groups or a control group receiving routine care. Standardized protocols will be applied for each intervention to ensure consistency.\n\nThe primary outcomes of this study include obstetric recovery, pain intensity, and gastrointestinal symptoms. By evaluating these outcomes simultaneously, the study aims to provide a more comprehensive understanding of post-cesarean recovery.\n\nThe findings of this study are expected to contribute to evidence-based clinical practice by identifying effective, safe, and feasible non-pharmacological interventions that can be integrated into routine post-cesarean care. Ultimately, this research may help improve maternal comfort, accelerate recovery, and enhance the overall postpartum experience for women undergoing cesarean section.",[171,172,173,28],"Cesarean Section","Cesarean Section Pain","Obstetric Recovery",[171,173,175,28,176,177,178,179],"Postoperative Pain","Music Therapy","Breathing Exercises","Virtual Reality","Postpartum Care","2026-04-26",{"date":182,"type":37},"2026-04-30",{"date":184,"type":20},"2026-05",{"date":186,"type":20},"2027-03",{"name":188,"class":44},"Selcuk University",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":15,"sex":16,"minAge":77,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":103},"100627837","the-effect-of-a-synbiotic-on-intestinal-barrier-function-and-microbiota-modulation-in-middle-aged-to-elderly-individuals-with-excessive-body-weight-100627837","NCT07453823","The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight","The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight: a Randomized, Double-blind, Placebo-controlled Study","myBIOM","Inclusion Criteria:\n\n1. Be able to give informed consent.\n2. Be between 50 to 70 years of age (inclusive).\n3. BMI ranging from 25.0 and 35.0 kg\u002Fm²\n4. Willing to maintain current level of physical activity and diet during the participation in the study.\n5. Experience ≤3 bowel movements per week within the month prior to screening\n6. Participants reported subclinical mild to moderate gastrointestinal complaints as defined by GSRS-IBS score 20-45 at screening.\n7. Willing to consume the study product daily for the duration of the study.\n8. Willing to eat the same meal the evening before visiting site (visit 2 to visit 5).\n\nParticipants are eligible for randomization if they fulfill the following two criteria based on the diary recordings during the run-in period prior to visit 2 9. Average GSRS-IBS composite symptom score between 20-45 during the two-week run-in period Record ≤6 bowel movements in the daily diary during the two-week run-in period\n\nExclusion Criteria:\n\n1. Has a history of drug and\u002For alcohol abuse.\n2. Has food allergies, or other issues with foods, that would preclude intake of the study products.\n3. Smoking, chewable tobacco and\u002For vaping and\u002For use of other nicotine products.\n4. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:\n\n   1. diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)\n   2. GI surgery that might have an effect on gastrointestinal tract function except cholecystectomy and appendectomy in the past 5 years or any major bowel resection at any time.\n   3. history of CVD\n   4. uncontrolled hypertension\n5. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:\n\n   1. systemic antimicrobial medication (including suppositories) within 4 weeks prior to visit 1\n   2. OTC medications, for digestive symptoms such as PPIs, anti-spasmodics, laxatives, anti-diarrheic drugs within 2 weeks prior to visit 1\n\n10\\. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.\n\n11\\. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.\n\nc. immunosuppressant drugs within the 4 weeks prior to the visit 1 d. systemic steroids within the 4 weeks prior to the visit 1 6. Regular oral non-steroidal anti-inflammatory (NSAIDs) within 1 week prior to visit 1 (topical NSAIDS allowed, Low-dose prophylactic aspirin use is acceptable if stable for 3 months prior to screening.) 7. Current or recent (in the past 4 weeks prior to visit 1) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, including:\n\na. Herbal supplements for digestive symptoms b. Large doses of vitamins and minerals, unless in stable dose c. Probiotic supplements d. Iron supplements 8. Current or recent (in the past 2-weeks) use of prohibited foods including yoghurts containing probiotics.\n\n9\\. Planned major changes in lifestyle \\[i.e., diet (e.g. start of fibre-enriched diet), dieting, exercise level, travelling\\] during the duration of the study.","70 Years",{"count":199,"type":20},90,[23],"The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults with excessive body weight. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.\n\nThe aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.",[203,28],"Gastrointestinal Microbiome (Focus)",[205,206],"Gastrointestinal Microbiome","Synbiotic","2026-04-14",{"date":209,"type":37},"2026-04-15",{"date":211,"type":37},"2026-03-18",{"date":39,"type":20},{"name":214,"class":67},"Chr Hansen - part of Novonesis",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":15,"sex":112,"minAge":223,"maxAge":137,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100633580","foot-reflexology-and-acupressure-on-gastrointestinal-symptoms-100633580","NCT07528534","Foot Reflexology and Acupressure on Gastrointestinal Symptoms","The Effect of Foot Reflexology and Acupressure on Gastrointestinal Symptoms in Menopausal Women","Menopausal","Inclusion Criteria:\n\n* Being between 45 and 60 years of age,\n* Being in menopause,\n* Experiencing gastrointestinal symptoms,\n* Agreeing to participate in the study voluntarily.\n\nExclusion Criteria:\n\n* Individuals with chronic gastrointestinal disease,\n* Individuals receiving regular medication will not be included in the study.","45 Years",{"count":225,"type":20},120,[23],"This research was planned to evaluate the effects of foot reflexology and acupressure applications on gastrointestinal symptoms in women going through menopause. Menopause is a period in which a woman experiences profound changes in her physiological, psychological, and social life due to the decrease in estrogen and progesterone hormones. Changes in digestive system functions are particularly common during this period; gastrointestinal symptoms such as constipation, bloating, heartburn, indigestion, and abdominal pain significantly reduce the quality of life.\n\nThe scope of the study focuses on investigating the manageability of these symptoms that occur during menopause with reflexology and acupressure, which are complementary and alternative medicine methods. Reflexology is a method based on the assumption that specific points on the soles of the feet are connected to the relevant organs in the body, aiming to increase blood circulation and regulate organ functions. Acupressure, based on Chinese medicine, aims to regulate energy flow and reduce symptoms by applying finger pressure to specific acupuncture points. Both methods are increasingly recommended for symptom management during menopause due to their non-invasive nature, low side effects, and ease of application.\n\nThis research will be conducted at Osmaniye State Hospital and will be limited to menopausal women who apply to this institution. Participants' demographic characteristics, duration of menopause, health history, and gastrointestinal symptom levels will be assessed using a Demographic Information Form and the Gastrointestinal Symptom Rating Scale (GSRS). The application process will be carried out in accordance with standard reflexology and acupressure protocols, and changes in symptoms will be analyzed using pre-test and post-test measurements. The study also aims to reveal the effects of gastrointestinal symptoms experienced during menopause on women's quality of life; This study aims to provide evidence-based data on complementary methods that can be integrated into nursing care, in addition to pharmacological treatments. The limited number of studies in the literature addressing the effects of complementary medicine practices during menopause makes this research unique from both a clinical and academic perspective.",[28],[230,231,232,233,234,235],"Menopause","Reflexology","Acupressure","Gastrointestinal symptoms","Complementary therapies","Women's health","2026-04-07",{"date":207,"type":37},{"date":209,"type":20},{"date":240,"type":20},"2026-06-15",{"name":242,"class":44},"Osmaniye Korkut Ata University",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":103},"100588163","the-effect-of-humiome-post-lb-on-gut-comfort-in-healthy-adult-volunteers-100588163","NCT06937814","The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers","The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers: a Double-blind, Randomized Placebo-controlled Study","Inclusion Criteria:\n\n1. Be able to give written informed consent.\n2. Self-reported gastrointestinal issues defined as 10-20 bowel movements per week and a score of 5-6 for ≥20% of stools based on the BSS in the 2 weeks prior to baseline, as assessed by the Qualified Investigator (QI).\n3. Self-reported GI issues such as bloating, mild cramping, and urgency, as assessed by the QI.\n4. Be between 18 and 75 years of age, inclusive.\n5. Have a BMI of between 18.5 - 29.9 kg\u002Fm2, inclusive.\n6. Self-reported stable body weight (\\\u003C5% change) over the past 3 months.\n7. Be in general good health, as determined by the QI.\n8. Willing to avoid consuming prebiotic, probiotic, postbiotics, fiber-rich and dietary supplements, anti-diarrheal and anti-constipation medication until the end of the study (see Section 5.6).\n9. Willing to maintain current dietary habits and lifestyle, including level of physical activity, allowed medication\u002Fsupplements habits for the duration of the study.\n10. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\nIndividuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n\n* Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n* Double-barrier method\n* Intrauterine devices\n* Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n* Vasectomy of partner at least 6 months prior to screening\n* Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n\nExclusion Criteria:\n\n1. Failure to meet any one of the inclusion criteria.\n2. Females who are pregnant, lactating or wish to become pregnant during the study.\n3. Are lactose intolerant or have any other hypersensitivity\u002Fallergy to any of the components of the test product.\n4. Meeting Irritable Bowel Syndrome (IBS) diagnostic criteria as defined by Rome IV criteria, i.e. having recurrent abdominal pain on average at least 1 day\u002Fweek in the last 3 months, associated with two or more of the following criteria:\n\n   1. Related to defecation.\n   2. Associated with a change in frequency of stool.\n   3. Associated with a change in form (appearance) of stool. Criteria need to be fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.\n5. Have suffered from diarrhea (defined as ≥3 bowel movements per day and 6-7 on BSS) at any time two weeks prior to run-in, as assessed by the QI.\n6. Experience alarm features such as weight loss, rectal bleeding, or recent change in bowel habit (\\\u003C3 months), as assessed by the QI.\n7. Have taken antibiotics within the previous 2 months prior to the run-in period as assessed by QI (see Section 5.6.1).\n8. Unstable hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg). Treatment on a stable dose of medication for at least 3 months will be considered by the QI.\n9. Known history of or ongoing HIV, hepatitis or clinically important, as judged by the QI, endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary conditions.\n10. Current or history of any significant diseases of the gastrointestinal tract (including but not limited to Crohn's disease, ulcerative colitis, celiacs disease, colectomy), as assessed by the QI.\n11. Have planned a major surgery during the study period as assessed by the QI.\n12. Have a history of drug and\u002For alcohol abuse in the past 12 months at the time of enrolment.\n13. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n14. Have made any major dietary changes in the past 3 months prior to run-in period.\n15. Currently consuming a vegetarian or vegan diet.\n16. Are planning a holiday over the study period that would alter dietary patterns as assessed by the QI.\n17. Have planned major changes in lifestyle (i.e. diet, weight loss program, exercise level, travelling) during the duration of the study.\n18. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period.\n19. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to abstain for the duration of the study period.\n20. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant.\n21. Participation in other clinical research studies 30 days prior to the run-in period, as assessed by the QI.","75 Years",{"count":252,"type":20},250,[23],"The goal of this double-blind, randomized placebo-controlled study is to evaluate the effect of an 8-week supplementation of Humiome ® Post LB (170 mg) on bowel movements in healthy adult volunteers compared to Placebo adjusted on baseline. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nDoes Humiome ® Post LB improve bowel movements with self-reported GI issues?\n\nParticipants will be provided Humiome ® Post LB (170 mg) for 8 weeks and asked to complete a study diary, questionnaires, and stool samples.",[256,257,28],"GI Issues","Bowel Movements",[259,233,260],"Bowel movements","Bristol stool scale","2026-03-05",{"date":263,"type":37},"2026-03-09",{"date":265,"type":37},"2025-06-16",{"date":267,"type":20},"2026-04",{"name":269,"class":67},"dsm-firmenich Switzerland AG",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":103},"100625358","an-8-week-study-evaluating-gut-and-digestive-health-after-use-of-a-dietary-supplement-system-100625358","NCT07421596","An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System","An Eight-week Clinical Study for the Measurement of Gut and Digestive Health Parameters Before and After the Use of a Dietary Supplement System","Inclusion Criteria:\n\n* 1\\. Male or female adults aged 18 to 80 years (considering 50% men and 50% women, even breakdowns in age groups 18-30, 31-60, 61-80 years, and 12-15% African American required) at the time of screening.\n\n  2\\. Willing and able to provide written informed consent before participation in any study-related procedures.\n\n  3\\. Willing and able to comply with all study procedures, including clinic visits, completion of questionnaires, and stool sample collection at predetermined time points.\n\n  4\\. Willing to collect and provide stool samples, either in-clinic or at home as instructed.\n\n  5\\. Willing to abstain from alcohol consumption (including beer, wine, and spirits) for the duration of the study.\n\n  6\\. Proficient in written and spoken English. 7. Willing to provide a valid email address and mobile phone number and able to complete electronic forms and questionnaires using a smartphone.\n\n  8\\. Able and willing to travel to the Research Institute for in-clinic visits and stool sample collection as scheduled.\n\n  9\\. No known food allergies, based on subject self-report. 10. Willing to maintain usual diet and lifestyle habits, except as required by the study protocol.\n\n  11\\. Subjects with self-reported gastrointestinal symptoms, defined as a baseline Gastrointestinal Symptom Rating Scale (GSRS) score ≥ 8 (35 subjects) and score ≤ 3 (5 subjects).\n\nExclusion Criteria:\n\n* 1\\. Known allergy or hypersensitivity to any ingredient(s) of the study product or other herbal products.\n\n  2\\. Presence or history of any medical condition that may interfere with study participation or outcome interpretation, including but not limited to:\n  * Malabsorption disorders\n  * Chronic gastrointestinal diseases\n  * Severe depression\n  * Clinically significant cardiovascular disease within the past 3 months 3. Pregnant, breastfeeding, or planning to become pregnant during the study period, based on subject self-report.\n\n    4\\. Having a pregnant partner or a partner who is planning to become pregnant during the study period and is unwilling or unable to use an acceptable method of contraception.\n\n    5\\. History of any cancer within the past 5 years. 6. Active or occasional smoking. 7. Current use of probiotics, unless willing to discontinue use at least 4 weeks prior to study enrollment.\n\n    8\\. History of weight loss surgery or any type of bowel surgery, including resection or colectomy.\n\n    9\\. Any active infection within the past 3 months requiring antibiotics, antiviral medication, or hospitalization.\n\n    10\\. Use of immunosuppressive medications within the past 12 months, including systemic corticosteroids or biologic agents.\n\n    11\\. History of seizure disorder or use of seizure medication within the past 4 weeks.\n\n    12\\. History of HIV infection or solid organ transplantation. 13. Use of medications for chronic gastrointestinal or digestive conditions, including but not limited to:\n  * Proton pump inhibitors or antacids (e.g., omeprazole, Prilosec®)\n  * Laxatives or gastrointestinal motility agents\n  * Medications for irritable bowel syndrome (IBS), Crohn's disease, or history of hospitalized diverticulitis 14. Any other condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation or compromise subject safety or study integrity.","80 Years",{"count":279,"type":20},50,[23],"This clinical research study is being conducted to evaluate gut and digestive health before and after the use of a dietary supplement system over an eight-week period.\n\nGut and digestive health play an important role in overall health, including digestion, nutrient absorption, immune function, and metabolic balance. Changes in gut microbiota, inflammation, and intestinal barrier function may contribute to digestive symptoms such as bloating, discomfort, altered bowel habits, and reduced well-being.\n\nIn this study, adult men and women with self-reported gastrointestinal symptoms will consume a dietary supplement system daily for eight weeks. The study will measure changes in gut and digestive health using objective stool-based laboratory biomarkers and validated symptom questionnaires.\n\nStool samples will be collected at baseline and at the end of the study to evaluate markers related to microbial diversity, inflammation, immune activity, digestive function, and intestinal barrier integrity. Participants will also complete questionnaires throughout the study to assess gastrointestinal symptoms and subjective digestive health and well-being.\n\nThe study will also monitor the safety and tolerability of the dietary supplement system during the study period.",[28,283,29],"Digestive Health",[285,286,287,288],"Stool biomarkers","Probiotics","Subjective digestive health","Gut Zoomer stool test","2026-02-22",{"date":291,"type":37},"2026-02-24",{"date":293,"type":20},"2026-02-05",{"date":295,"type":20},"2026-04-21",{"name":297,"class":298},"SF Research Institute, Inc.","NETWORK",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":21,"phases":309,"briefSummary":310,"conditions":311,"keywords":317,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":103},"100625397","pan-clo-bu-pancreas-clostridium-butyricum-100625397","NCT07422103","PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)","Supplementation With Clostridium Butyricum CBM588 in Patients Undergoing Pancreaticoduodenectomy for Periampullary Neoplasms: A Prospective Randomized Double-Blind Study","PAN-CLO-BU","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Patients undergoing pancreaticoduodenectomy\n* Candidates for upfront surgery without previous neoadjuvant chemotherapy or radiotherapy\n* Patients with benign or malignant periampullary neoplasms\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Previous or current use of Clostridium butyricum CBM588\n* Lactose intolerance\n* Neoadjuvant chemotherapy or radiotherapy",{"count":308,"type":20},158,[23],"This is a prospective, randomized, double-blind, single-center clinical trial designed to evaluate the effects of Clostridium butyricum CBM588 supplementation on postoperative diarrhea, gastrointestinal symptoms, and quality of life in patients undergoing pancreaticoduodenectomy for periampullary neoplasms. Oncological outcomes, including disease-free survival and overall survival, will be monitored as secondary endpoints during follow-up.",[312,313,28,314,315,316],"Pancreatic Cancer","Pancreatic Diseases","Clostridium Butyricum Miyairi","Pancreatoduodenectomy","CBM588",[312,313,28,314],"2026-02-12",{"date":320,"type":37},"2026-02-19",{"date":322,"type":20},"2026-03-15",{"date":324,"type":20},"2030-11-30",{"name":326,"class":44},"Casa di Cura Dott. Pederzoli",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":103},"100622774","evaluating-the-ability-of-a-multi-strain-postbiotic-to-impact-inflammation-immune-components-gastrointestinal-symptoms-recovery-anxiety-and-intestinal-permeability-100622774","NCT07387991","Evaluating the Ability of a Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms, Recovery, Anxiety, and Intestinal Permeability","Clinical Trial to Evaluate the Ability of Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms, Recovery, Anxiety, and Intestinal Permeability","BIO","Inclusion Criteria:\n\nHealthy males and females aged 18 to 55 years of age. Individual indicates they are physically active defined as: 30 minutes of moderate intensity activity 4 days per week in the past 3 months.\n\nSubject has the ability to exercise on a treadmill without issue or concern. Body Mass Index (BMI) 18.0-32.0 kg\u002Fm2 (normal weight to obesity weight). The average BMI of the entire cohort will be \\\u003C30.0 kg\u002Fm2.\n\nSubject is in good health and appropriate for exercise as determined by physical examination and medical history.\n\nSubject can exercise on a treadmill without issue or concern. Subject is a non-smoker. Subject agrees to not use any new vitamin, mineral, or dietary supplements 24 hours prior to the exercise test visits.\n\nSubject is willing and able to comply with the protocol including: attending the study scheduled appointments, of which two of the study visits may take up to four hours of completion.\n\nSubject agrees to refrain from exercise for the 24 hours prior to any test visits.\n\nSubject agrees to refrain from alcohol use for at least 24 hours before every study visit.\n\nSubject is able to understand and sign the informed consent to participate in the study.\n\nExclusion Criteria:\n\nIndividuals who are determined to have liver, renal, cardiovascular, or other metabolic disease.\n\nUse of any dietary supplements, prescription mediation (particularly antibiotics and\u002For anti-inflammatories), or probiotics within the past 2 months which may confound the study or its endpoints.\n\nAlcohol consumption (\\>2 standard alcoholic drinks\u002Fday or \\>10 drinks\u002Fweek) or drug abuse\u002Fdependence.\n\nSmokers (defined as greater than 2 cigarettes per day for past 90 days). Clinically significant abnormal laboratory results at screening. Allergy or sensitivity to study supplement ingredients. Individuals who are cognitively impaired and\u002For who are unable to give informed consent.\n\nIndividuals with diabetes, asthma, rheumatoid arthritis, colitis, IBS\u002FIBD, gout, or fibromyalgia.\n\nAny other condition which in the PI's opinion may adversely affect the subject's ability to complete the study, its measurement or poses significant risk to the subject.","55 Years",{"count":279,"type":20},[23],"This study will evaluate the effects of a multi-strain postbiotic supplement on markers of inflammation, immune function, gastrointestinal symptoms, psychological well-being, and intestinal permeability in healthy adults. The primary objective is to determine whether four weeks of postbiotic supplementation alters physiological and perceptual responses to a standardized bout of moderate-to-high intensity exercise compared with placebo.\n\nApproximately 50 healthy men and women aged 18 to 55 years will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Participants will be randomly assigned to receive either a multi-strain postbiotic supplement or a matched placebo for 28 days.\n\nAt the end of the supplementation period, participants will complete a 45-minute treadmill exercise bout at 75% of their individually determined maximum heart rate. Blood samples will be collected to assess biomarkers of inflammation, immune activity, and recovery. Gastrointestinal symptoms, intestinal permeability, anxiety, and perceived recovery will be evaluated using validated questionnaires.\n\nThis study is designed to determine whether postbiotic supplementation modulates physiological stress responses and subjective well-being following prolonged exercise in healthy adults.",[340,28],"Inflammation","2026-01-28",{"date":343,"type":37},"2026-02-04",{"date":345,"type":20},"2026-06-01",{"date":347,"type":20},"2027-06-01",{"name":349,"class":44},"Lindenwood University",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":358,"targetDuration":4,"studyType":21,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":369,"locationsCount":103},"100622795","impact-of-weizmannia-bacillus-coagulans-jbi-yz63-on-gut-health-and-fecal-microbiome-changes-100622795","NCT07388264","Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","Examining the Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes","WIZ","Inclusion Criteria Ages of 18 - 50 years Average daily bloating score \\>5 on question 3 of the Modified daily Abdominal, Gas, and Bloating Questionnaire and\u002For bloating for \\>5 days during the past 14 days Body mass index (BMI) 18.5 - 29.9 kg\u002Fm2 (Inclusive) (Individuals \\>29.9 kg\u002Fm2, but \\\u003C25% fat for men and \\\u003C30% fat for women will be accepted into the study. The cohort average of body mass index will not exceed 29.9 kg\u002Fm2) Weight stable for the past three months (defined as less than a 5% variation in body mass over this time) Determined to be healthy through completion of a health history questionnaire Subject agrees to maintain their existing dietary patterns throughout the study period and to report to study investigators any changes particularly as they relate to probiotic-containing or fermented foods Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours prior to each test day.\n\nMinimum baseline physical activity level (defined as at least 30 minutes of moderate intensity exercise at least 4 days per week for the past 3 months) Subject is willing and able to comply with the study protocol. Study participant is not currently enrolled in another clinical trial that involves the administration of some investigative agent Subject has given voluntary, written, informed consent to participate in the study.\n\nExclusion Criteria Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals Has liver disease or some form of clinically diagnosed hepatic impairment Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL) Diagnosed with or is being treated for some form of thyroid disease Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS) History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n\nParticipant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) Participant has been treated for a gastrointestinal related disorder, complication, or disorder within the past 30 days Positive medical history for any neurological condition or neurological disease Diagnosed with or being treated for any endocrinological disorder or currently used any form of hormone replacement (prescribed\u002Fdoctor ordered or not) Women with a history of hormone-related conditions such as endometriosis, fibroids, polycystic ovary syndrome Currently prescribed for the first time statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Currently prescribed for the first time hypertension medication (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.) within the past 6 months or has had their dosage or medication changed within the past 6 months Current antibiotic use or other prescription or over-the-counter medications that may impact study outcomes Have a known sensitivity or allergy to any of the study products Blood donation in past 60 days Current smoker (average of \\> 1 pack per week within the past 3 months) or has quit within the past six months. This includes all forms of nicotine They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study Competitive athletes will be excluded History of alcohol or substance abuse in the 12 months prior to screening Current use of anabolic steroids (medically prescribed or otherwise) Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol Report taking a probiotic or other dietary supplement know to impact digestion or gut function in the past 30 days Recent history (\\\u003C3 months) of exercise training or weight loss (\\> 5%) Currently following a ketogenic or low carbohydrate diet within the past 30 days.\n\nWomen who are pregnant, planning to become pregnant, or lactating currently or within the past six months Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data",{"count":359,"type":20},30,[23],"This study will evaluate the effects of supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 on gastrointestinal health in healthy, physically active adults. The primary objective is to determine whether daily intake of this probiotic strain improves symptoms of constipation and related gastrointestinal function compared with placebo.\n\nApproximately 30 healthy men and women aged 18 to 50 years will be enrolled in a randomized, double-blind, placebo-controlled, crossover trial. Participants will complete two 4-week supplementation periods, one with Weizmannia (Bacillus) coagulans JBI-YZ6.3 and one with placebo, separated by a 4-week washout period. The total duration of participation will be approximately 13 to 14 weeks, including screening and testing visits.\n\nGastrointestinal symptoms will be assessed at baseline and after each supplementation period using validated questionnaires, with particular focus on the constipation domain of the Gastrointestinal Symptom Rating Scale (GSRS). Secondary outcomes will include additional gastrointestinal symptom domains and markers of perceived gut comfort and function.\n\nThis study is designed to determine whether supplementation with Weizmannia (Bacillus) coagulans JBI-YZ6.3 produces clinically meaningful improvements in gastrointestinal symptoms in physically active adults compared with placebo.",[28,363,29,364],"Constipation","Gastrointestinal Function",{"date":293,"type":37},{"date":367,"type":37},"2025-06-15",{"date":240,"type":20},{"name":349,"class":44},{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":15,"sex":112,"minAge":17,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":391,"locationsCount":103},"100621154","phase-1-the-effect-of-daily-supplementation-with-humiome-post-lb-on-gastrointestinal-symptoms-in-female-athletes-100621154","NCT07366931","The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes","A Randomized, Placebo-controlled, Double-blind Trial on the Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes","GI-Jane","Inclusion Criteria:\n\n1. Female, cisgender, premenopausal.\n2. Minimum age 18 years.\n3. Regular, natural menstrual cycle (21-35 days in duration), with 9 or more consecutive periods per year, if possible documented with tracker apps, calendars, or other tools.\n4. Willingness and ability to give informed consent and to understand, to participate, and to comply with the clinical study requirements.\n5. Body mass index (BMI) ≥ 18.5 and \\\u003C 24.9 kg\u002Fm2\n6. Agreeing to maintain lifestyle habits during the study (same dietary and physical activity habits)\n7. Having a smartphone and a history of consistent tracking of training and health records via apps.\n8. Having regular GI issues during exercise, preferably also during menstruation. During pre-screening, this will be assessed with a shortened GSRS questionnaire, where participants need to have had, in the month preceding pre-screening, the equivalent of at least a score of 2 in a GSRS focus area (diarrhoea, pain, indigestion).\n9. No relevant self-reported abnormalities from medical history.\n10. Trained athlete (trains at least 3 times per week for more than 1 hour per day and who has been involved in endurance training for at least 2 years in alignment with previous research (Pfeiffer et al., 2010). This will be evaluated by assessing training records (Strava or similar application, certificates of attendance to athletic events, club membership, etc.).\n11. Access to a health-care provider, who can be contacted by the CRO, and who reside in areas with available health services.\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, lactating, or plan to become pregnant before study end.\n2. Individuals with secondary amenorrhea.\n3. Individuals who use hormonal contraceptives during the last 6 months before (and during) the trial.\n4. Individuals who are currently participating in another clinical trial or have participated in a trial within the last two months prior to enrolment.\n5. Tobacco smokers and vapers.\n6. Individuals with acute illness.\n7. Individuals with a current musculoskeletal injury or one within the last month.\n8. Individuals taking probiotic supplements or who have taken probiotics two weeks prior to enrolment.\n9. Individuals controlling chronic diseases with treatments known to alter the intestinal microbiome or to alter GI symptoms, such as certain pain killers, antacids, proton-pump inhibitors, anti-diarrhoeal medication or supplements, and laxatives.\n10. Individuals having received antibiotics treatments within three months of trial start.\n11. Individuals having planned major changes in lifestyle (i.e. diet, weight loss program, exercise level, travelling) during the duration of the study.\n12. Individuals who have any hypersensitivity\u002Fallergy to any of the components of the test product.\n13. Individuals who have planned major elective surgery during the study period.",{"count":114,"type":20},[380,381],"PHASE1","PHASE2","Female athletes are often overlooked in scientific research, including the understanding of their digestive system and its impact on overall health, training, and performance. The gastrointestinal (GI) system plays a critical role in supporting digestion, nutrient absorption, and acting as a protective barrier for the body. While there is some knowledge about the differences in GI structure and function between males and females at rest, there is a lack of understanding regarding how these differences manifest during exercise, especially among female athletes and at different phases of the menstrual cycle.\n\nIt has been observed that female athletes commonly report a higher prevalence of GI symptoms compared to males, with many experiencing an increase during menstruation. These symptoms, including bloating, abdominal discomfort, and irregular bowel movements, can significantly disrupt an athlete's training and performance. Elite female athletes have acknowledged that GI symptoms associated with the menstrual cycle have led to altered or disrupted training routines. While these symptoms are commonly recognized to affect a large portion of the female population, few interventions have been studied to assist in managing this discomfort. Some clinicians may direct their patients to take pain-relieving medications without any thoughts on the consequences of chronic use.\n\nOne potential strategy to reduce GI symptoms during endurance exercise is probiotic-postbiotic supplementation. Various probiotic supplements have been shown to effectively decrease diarrhoea, constipation stress, and intestinal permeability, as well as impact immunologic outcomes. Postbiotics differ from probiotics in that they are made from microorganisms that are not alive. They allow the modulation of the composition and function of the gut microbiota and enhance the intestinal barrier to prevent unwanted substances from entering the body proper. While these biotics can relieve lower GI symptoms in irritable bowel syndrome (IBS), there is less consensus regarding their efficacy in modulating exercise-associated GI symptoms. Previous research by Pugh et al., 2019 has demonstrated that four weeks of probiotic supplementation was able to reduce GI symptoms during a marathon race, however this work was predominantly conducted in males and did not take menstrual cycle in consideration. This is important given that symptoms are commonly higher in the early follicular phase when a female experiences their period. Therefore, the aim of this study is to assess the effects of postbiotic supplementation on GI symptomology in female athletes.\n\nThe aim of this present study is to investigate the influence of postbiotic supplementation on menstrual cycle symptoms and exercise-associated GI symptoms in female endurance athletes while exercising compared to symptoms while taking a placebo.",[384,28],"Healthy Adult Females","2026-01-24",{"date":387,"type":37},"2026-01-27",{"date":389,"type":20},"2026-01-01",{"date":156,"type":20},{"name":128,"class":44},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":16,"minAge":400,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":21,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":103},"100621468","fecal-microbiota-transplantation-in-children-with-autism-spectrum-disorder-and-gastrointestinal-symptoms-100621468","NCT07371013","Fecal Microbiota Transplantation in Children With Autism Spectrum Disorder and Gastrointestinal Symptoms","Fecal Microbiota Transplantation in Children With Autism Spectrum Disorder and Gastrointestinal Symptoms: A Pilot Study","FMT-ASD-GI","Inclusion Criteria:\n\n* Providing informed consent for participation in the study by the child's legal representative - parent or legal guardian.\n* Diagnosis of autism spectrum disorder according to DSM-5 or ICD-11 criteria.\n* Ability to swallow an empty test capsule identical in shape and size to the investigational product\n* Abnormal stool consistency observed by parents for at least 2 months prior to study inclusion.\n\nPatients with an average stool consistency greater than 5 on the Bristol Stool Form Scale (BSFS) during the baseline period will be classified as having diarrhea.\n\nPatients with an average stool consistency less than 3 on the Bristol Stool Form Scale during the baseline period will be classified as having constipation.\n\nExclusion Criteria:\n\n* Presence of a gastrointestinal disease such as celiac disease, food allergy, inflammatory bowel disease, pancreatitis, chronic liver disease, eosinophilic esophagitis, peptic ulcer disease of the stomach or duodenum, Hirschsprung's disease.\n* Primary or secondary immunodeficiency, including absolute neutrophil count in peripheral blood \\\u003C1500 measured within 28 days prior to planned FMT.\n* History of surgery involving disruption of intestinal continuity within 3 months prior to study inclusion.\n* Lactose or fructose intolerance. Patients with lactose intolerance who follow an elimination diet and still experience symptoms may be included in the study.\n* Malnutrition defined as Body Mass Index (BMI) below the 3rd percentile based on Polish growth charts from 2010.\n* Overweight or obesity defined as BMI above the 85th percentile based on Polish growth charts from 2010.\n* Active infection requiring antibiotic therapy.\n* Expected use of antibiotics during participation in the study.\n* Use of probiotics during participation in the study.\n* Inability to undergo bowel cleansing therapy (Dicopeg Endo).\n* Inability to swallow an empty test capsule.\n* Lack of consent from the child's legal representative - parent or legal guardian - for participation in the study.","6 Years","12 Years",{"count":403,"type":20},20,[23],"The aim of the study is to evaluate the effectiveness and safety of fecal microbiota transplantation (FMT) in reducing gastrointestinal (GI) and behavioral symptoms in children with autism spectrum disorder (ASD).\n\nChildren with ASD often experience GI problems such as constipation, diarrhea, and abdominal pain. These symptoms can negatively affect their daily life and behavior. Recent research suggests that the gut microbiota-the community of bacteria and other microorganisms living in the intestines-plays an important role in digestion, immunity, and communication with the brain through the gut-brain axis. Modifying the gut microbiota may help improve GI symptoms and possibly behavioral functioning.\n\nFMT involves giving a preparation containing gut microbiota from a healthy donor after bowel cleansing. The product used in this study is MBiotix HBI Caps, produced by Human Biome Institute. A placebo (inactive substance) will also be used for comparison. Both will be given as frozen oral capsules that look identical.\n\n20 children aged 6-12 years will take part. Participants will be randomly assigned to receive either the microbiota preparation or placebo. The study includes several visits over about 6 months. Before the first dose, every child will undergo bowel cleansing with a special preparation (Polyethylene Glycol, PEG). During the study, participants will be asked to keep a symptom diary, complete questionnaires, and record child's diet. Biological samples (stool, urine, saliva) will be collected at specific time points for analysis. Every child will also be assessed by a psychologist before the study begins and again during the study using standardized tools (Autism Diagnostic Observation Schedule, Second Edition, ADOS-2) to evaluate behavioral functioning and quality of life.",[407,28],"Autism Spectrum Disorder",[409,410,411,412],"fmt","asd","gi","autism","2026-01-22",{"date":387,"type":37},{"date":416,"type":20},"2026-01",{"date":186,"type":20},{"name":419,"class":44},"Institute of Mother and Child, Warsaw, Poland",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":112,"minAge":17,"maxAge":137,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":439,"leadSponsor":441,"locationsCount":103},"100621447","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-bloat-on-gas-and-bloating-in-healthy-women-100621447","NCT07370740","A Clinical Trial to Investigate the Safety and Efficacy of Bloat on Gas and Bloating in Healthy Women","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Bloat on Gas and Bloating in Healthy Women","Inclusion Criteria:\n\n1. Females aged 18-65 years, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least one year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. Recurrent bloating and\u002For distension occurring on average at least one day per week which predominates over other GI symptoms as assessed by the QI\n4. Experiences significant gas and bloating after consumption of the standardized meal provided at screening\u002Fbaseline, as assessed by a score of 0 (absent) or 1 (mild) pre-meal and a score of 2 (moderate) or 3 (severe) post-meal\n5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n6. Provided voluntary, written, informed consent to participate in the study\n7. Healthy as determined by medical history as assessed by Qualified Investigator\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)\n3. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of IP, placebo, or standardized meal ingredients\n4. Current or history of any significant diseases of the GI tract or digestive disorders (e.g., irritable bowel syndrome, celiac disease, inflammatory bowel disease, functional constipation, gastroesophageal reflux disease, being treated within the past year for H. pylori infection or gastric ulcer) as assessed by the QI\n5. Unstable metabolic disease or chronic diseases as assessed by the QI\n6. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n7. Type I or Type II diabetes\n8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n9. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n10. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n11. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n12. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n13. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n14. Chronic use of cannabinoid products (\\>2 times\u002Fweek) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n15. Regular use of tobacco or nicotine products in the past 6 months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n16. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n17. Alcohol or drug abuse within the last 12 months\n18. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the IP (Section 7.3)\n19. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n20. Individuals who are unable to give informed consent\n21. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":114,"type":20},[23],"The goal of this clinical trial is to investigate the safety and efficacy of Bloat on gas and bloating in healthy women. The main question it aims to answer is what is the change in postprandial gas and bloating from pre-dose at t = 60 mins post-dose between Bloat and placebo, as assessed by Gas and Bloating Likert scale at screening\u002Fbaseline.\n\nParticipants will be asked to consume one dose of Bloat or Placebo and answer questionnaires on gas and bloating.",[431,28,432],"Bloating","Intestinal Gas",[434,435,431,432,233],"Bloat","Arrae","2026-01-21",{"date":387,"type":37},{"date":184,"type":20},{"date":440,"type":20},"2026-07",{"name":435,"class":67},{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":15,"sex":16,"minAge":450,"maxAge":451,"enrollmentInfo":452,"targetDuration":4,"studyType":21,"phases":454,"briefSummary":455,"conditions":456,"keywords":461,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":103},"100619311","gastrointestinal-symptoms-and-tolerance-in-infants-fed-goat-or-cows-milk-based-infant-formula-100619311","NCT07342972","Gastrointestinal Symptoms and Tolerance in Infants Fed Goat or Cow's Milk-based Infant Formula","Effect of a Goat-milk Based Infant Formula on Gastrointestinal Symptoms and Tolerability in Healthy Term Infants: a Double-blind Randomized Controlled Trial","MESK-2","Inclusion Criteria:\n\n* Age between 14 days and 90 days.\n* Healthy singleton term infants born between 37 weeks and 42 weeks of gestation.\n* Infants who have received CMF for at least 7 consecutive days.\n* Exclusive formula feeding.\n* Cow's Milk-related Symptoms Score (CoMiSS®) value at baseline of ≥6 and \\\u003C10.\n* Parents' or caregivers, aged ≥18 years, willing to give informed consent and adhere to study protocol\n\nExclusion Criteria:\n\n* Exclusively or partially feeding with human milk\n* Introduced to solid food, supplementary feeding, use of pre- and\u002For probiotics as a supplement\n* Congenital or recurrent chronic conditions and\u002For malabsorption that could interfere with study parameters.\n* Diagnosed cow's milk allergy (CMA) or suspected to have CMA, soy allergy, fish allergy, egg allergy and\u002For lactose intolerance.\n* Receiving medication (on own initiative or prescription) with regard to FGID (i.e. reflux medication)\n* Sibling already participating in this study\n* Participation in another clinical trial","14 Days","90 Days",{"count":453,"type":20},144,[23],"This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.",[457,28,458,459,460],"Gastrointestinal Tolerance","Infections","Quality of Life","Anthropometrics",[462,463,464,465,233,466],"Formula","Infant","Goat milk-based infant formula","RCT","Gastrointestinal tolerance","2026-01-06",{"date":469,"type":37},"2026-01-15",{"date":471,"type":20},"2026-02",{"date":473,"type":20},"2027-09",{"name":475,"class":67},"Ausnutria Hyproca B.V.",{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":21,"phases":487,"briefSummary":488,"conditions":489,"keywords":493,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":4},"100614517","diagnostic-pcr-panel-in-children-with-acute-gastrointestinal-symptoms-100614517","NCT07280624","Diagnostic PCR Panel in Children With Acute Gastrointestinal Symptoms","Clinical Significance of Real Time PCR Panel in Children With Acute Gastrointestinal Symptoms","RealCAGI RCT","Inclusion Criteria:\n\n* Child or adolescent \\\u003C 16 years of age\n* Visiting pediatric ED\n* Presence of gastrointestinal symptom or symptoms (diarrhea, vomiting or abdominal pain)\n\nExclusion Criteria:\n\n* Need of cardiopulmonary resuscitation at the ED\n* Need of immediate transfer to the intensive care unit\n* Hemato-oncological disease\n* Severe immunosuppression\n* Bloody diarrhea\n* Clinical suspicion of typhoid\u002Fparatyphoid fever","16 Years",{"count":486,"type":20},526,[23],"This investigator-initiated randomized controlled trial compares the clinical impact of real time PCR of fecal samples in children with acute gastrointestinal symptoms at a pediatric emergency room. Specifically, the trial compares immediate testing of fecal samples using a multiplex PCR panel to a a control group with delayed test results.",[490,28,491,492],"Gastroenteritis Acute","Abdominal Pain\u002F Discomfort","Vomiting in Infants and\u002For Children",[494,495,496,497,498,499,233,500,501,502],"Multiplex PCR","Fecal samples","Diagnostic stewardship","Diarrhea","Vomiting","Abdominal pain","Pediatrics","Children","Emergency department","2025-12-09",{"date":505,"type":37},"2025-12-12",{"date":507,"type":20},"2025-12-15",{"date":509,"type":20},"2028-02-15",{"name":511,"class":44},"University of Oulu",{"id":513,"slug":514,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100613906","effect-of-h-pylori-eradication-on-the-improvement-of-gastrointestinal-symptoms-100613906","NCT07272681","Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms","Effect of Helicobacter Pylori Eradication on Gastrointestinal Symptoms in Adult Patients","HPE-GI","Inclusion Criteria:\n\n1. Adults aged 18 years and older.\n2. Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests.\n3. Presence of any upper or lower gastrointestinal symptoms.\n4. Willingness to undergo H. Pylori eradication therapy and follow-up.\n5. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Age less than 18 years.\n2. The previously unsuccessful application of empirical H. pylori eradication therapy.\n3. Use of non-steroidal anti-inflammatory drugs (NSAIDs).\n4. Any malignant disease of the stomach or any other site.\n5. Any associated comorbidity (renal insufficiency, mental illness).\n6. History of allergies to proton pump inhibitors or antibiotics.\n7. Refusal to participate in the survey.",{"count":114,"type":20},"This study aims to evaluate the effect of Helicobacter pylori eradication on gastrointestinal symptoms in adult patients. H. pylori infection is a common cause of dyspepsia and other upper gastrointestinal complaints. The trial will assess whether successful eradication therapy leads to significant improvement in symptoms compared to baseline. Adult patients diagnosed with H. pylori infection will receive standard eradication treatment, and symptom changes will be monitored using validated questionnaires over a defined follow-up period.",[523,524,28],"Helicobacter Pylori Infection","Dyspepsia","2025-12-08",{"date":527,"type":37},"2025-12-16",{"date":529,"type":20},"2025-12-20",{"date":531,"type":20},"2026-12-20",{"name":533,"class":44},"Amany Usama Ahmed Arafa",{"id":535,"slug":536,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":137,"enrollmentInfo":540,"targetDuration":4,"studyType":21,"phases":542,"briefSummary":543,"conditions":544,"keywords":547,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":103},"100513962","mechanisms-of-gulf-war-illness-100513962","NCT05972291","Mechanisms of Gulf War Illness","Inclusion Criteria:\n\n1. Veterans 18-65 years old with GWI and chronic GI symptoms (abdominal pain, diarrhea, bloating) that started during their deployment in the Persian Gulf\n2. Veterans 18-65 years old with GWI and chronic GI symptoms (abdominal pain, diarrhea, bloating)\n3. increased intestinal permeability on the lactulose\u002Fmannitol permeability test (ratio \\>0.07)\n4. able and willing to cooperate with the study\n\nExclusion Criteria:\n\n1. current participation in another research protocol or unable to give informed consent\n2. women with a positive urine pregnancy test or breastfeeding\n3. history of inflammatory bowel disease, lactose intolerance and\u002For celiac sprue\n4. \\+ hydrogen breath test for bacterial overgrowth\n5. \\+ anti-endomysial antibody titer\n6. use of NSAIDs 2 weeks before or during the study\n7. known allergy to glutamine or whey protein\n8. abdominal surgery except for removal of gallbladder, uterus, or appendix \\>6 months prior to entry into the study\n9. Abnormal serum BUN and\u002For creatinine\n10. Mannitol recovery out of the normal range of 5-25 U\u002Fg\n11. history of kidney disease\n12. allergies to monosodium glutamate\n13. current use of anti-seizure medications",{"count":541,"type":20},80,[23],"Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans. Our proposed studies will provide an innovative and novel treatment trial for chronic gastrointestinal symptoms in veterans with Gulf War Illness that were deployed into war zones. Given that there are currently no specific treatments for these disorders, and that current symptomatic approaches are far from ideal, proof of principle of our trial would be an extremely important advance as it would not only have a beneficial impact on the health of many thousands of our veterans, but also it would substantially reduce the many negative economic effects of this ailment on the VA Health Care System.",[545,546,28],"Gulf War Illness","Irritable Bowel Syndrome",[548,549,550],"gastrointestinal","irritable bowel syndrome","glutamine","2025-11-28",{"date":553,"type":37},"2025-12-05",{"date":555,"type":37},"2023-10-16",{"date":557,"type":20},"2027-07-31",{"name":559,"class":560},"VA Office of Research and Development","FED",{"id":562,"slug":563,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":15,"sex":112,"minAge":17,"maxAge":223,"enrollmentInfo":568,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":569,"conditions":570,"keywords":576,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":103},"100433065","mother-infant-cohort-study-in-malaysia-and-china-100433065","NCT04919265","Mother-Infant Cohort Study in Malaysia and China","Breastmilk, Infant Gut Microbiome and the Impact on Infant Health: a Prospective Mother-Infant Cohort Study in Malaysia and China","Inclusion Criteria:\n\n* Pregnant women aged between 18 and 45 years old\n* Pregnant women who attend the antenatal check-up at the selected clinics\u002Fhospitals\n* Pregnant women with the gestational age of less than 12 weeks\n* Pregnant women who plan to attend post-natal check-ups for at least one year at the same clinic\u002Fhospital\n\nExclusion Criteria:\n\n* Pregnant women who are diagnosed with immune deficiency\n* Pregnant women who have a multiple pregnancy and preterm delivery (\\\u003C37 weeks)\n* Pregnant women who plan to move out of the study area in the next one year\n* Pregnant women with fetal\u002Fnewborn with congenital abnormalities",{"count":19,"type":20},"This mother-infant cohort study aims to determine the geographic differences in the microbial profiles in breast milk from mothers living in Malaysia and China that are potentially important determinants of infant development. It also aims to determine the impact of gut microbiome on infant health (temperament, gastrointestinal symptoms, eczema symptoms, and asthma symptoms).",[571,28,572,573,574,575],"Gut Microbiota","Temperament","Eczema","Asthma","Breast Milk Collection",[93,577,578],"Mother-infant cohort study","Breastmilk","2024-12-09",{"date":581,"type":37},"2024-12-13",{"date":583,"type":37},"2022-06-03",{"date":39,"type":20},{"name":586,"class":44},"Universiti Putra Malaysia"]